Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe 7.5mg Mounjaro pen delivers its dose in 0.5ml of fluid — so if you've seen "7.5ml" on paperwork or a packing slip, that's likely a typo or a unit mix-up, and the medicine itself is the 7.5mg strength. Mounjaro (tirzepatide) is a prescription-only weight-management injection made by Eli Lilly, available in six strengths from 2.5mg up to 15mg. Each KwikPen contains four weekly doses. Reaching the 7.5mg strength means a prescriber has already assessed your progress at lower doses and judged that stepping up is clinically appropriate for you. These medicines require a prescription following a formal clinical assessment — a prescriber decides whether 7.5mg is the right next move, not the patient alone.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Yes, almost certainly. Mounjaro doses are measured in milligrams (mg), not millilitres (ml). The physical volume of each injection is 0.5ml regardless of which strength pen you're using, so a 2.5mg dose and a 15mg dose both push the same amount of liquid under the skin. The number that changes is the concentration of tirzepatide inside that 0.5ml.
If your prescription, a letter from a clinic, or an online order confirmation reads "7.5ml", it's worth checking against the label on the actual pen before injecting. The pen itself is clearly printed with the strength in mg; a quick ten-second glance at the barrel solves any confusion before it matters. If the documents and the pen disagree, contact the prescribing team before using anything.
For a full grounding in how Mounjaro works and what the broader treatment involves, the Mounjaro treatment overview covers the dual GIP and GLP-1 mechanism in plain language. The NHS also publishes a patient-level guide to tirzepatide at nhs.uk/medicines/tirzepatide that's worth bookmarking alongside your Patient Information Leaflet.
Mounjaro treatment always starts at 2.5mg. That first pen isn't really a therapeutic dose; its job is to let your digestive system adjust gradually, keeping early nausea manageable. Most people then move to 5mg after four weeks, and to 7.5mg after a further four, though the exact pace is set by the prescriber, not a fixed timetable. If 5mg is producing side effects that haven't settled, it's entirely reasonable to stay there longer.
By the time 7.5mg arrives, the mechanism is working meaningfully. Tirzepatide activates both GIP and GLP-1 receptors, which together slow gastric emptying and reduce appetite signalling. The higher the dose, the more pronounced those effects tend to be, which is why the SURMOUNT-1 trial, involving more than 2,500 adults with obesity, found that participants on the higher strengths achieved substantially greater average weight reduction than those on lower ones.
The step from 5mg to 7.5mg is one of the more common points where people notice a noticeable shift in appetite, so it's worth having realistic expectations: some people feel more nausea in the first week at a new dose, and that usually settles. Read the comparison of 5mg vs 7.5mg if you're weighing up whether to move up or stay where you are.
The side-effect profile at 7.5mg mirrors the rest of the Mounjaro schedule: nausea, loose stools, constipation, indigestion, reduced appetite and fatigue are the most commonly reported. Most people find these are at their worst in the first week after a dose increase and ease from there. Staying well hydrated and eating smaller, lower-fat meals helps considerably.
There are symptoms, though, that need prompt medical attention rather than watchful waiting. In January 2026 the MHRA issued a Drug Safety Update for GLP-1 medicines specifically highlighting acute pancreatitis: severe, persistent stomach pain (especially pain that reaches through to the back, with or without vomiting) warrants same-day medical assessment. Gallbladder symptoms, signs of significant dehydration (dark urine, dizziness, very little urine output), and any allergic reaction are also reasons to seek urgent help rather than continuing.
You can report any suspected side effect to the MHRA directly through the Yellow Card scheme. Our frequently asked questions cover a number of common concerns at each dose step, and our aftercare team is available seven days a week if something doesn't feel right.
The eligibility criteria for Mounjaro don't change between doses, a prescriber must judge you a suitable candidate before treatment starts, and that assessment accounts for BMI, any weight-related health conditions, and your overall medical picture. What the 7.5mg step does change is your position in the titration: you're past the settling-in phase and into the range where most people see meaningful progress.
On cost, it's worth knowing that Mounjaro's UK list price rose substantially in September 2025. Reported private prices since then range roughly £149 to £375 per month by dose and provider, so if price is a factor in your thinking, the guide to Mounjaro pricing in the UK sets out what those figures typically include, and, more usefully, what they often don't. A transparent price that covers the consultation, prescription and aftercare is a different proposition from a headline pen price with extras added later.
If you're already on treatment elsewhere and considering transferring, or if you're newer to this and wondering whether 7.5mg is where you'd be starting, our clinical team reviews every case individually. The 2.5mg Mounjaro page explains what the very beginning of treatment looks like, and the 5mg page covers the step before this one. When you're ready to talk it through, start a free consultation and a GPhC-registered prescriber will review your situation the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.